The company focuses on commercializing a technology that enables standardized access and closure of the heart's apex and peripheral vascular system, allowing for the delivery of large therapeutic devices into the inner chambers of the heart. With applications in various medical procedures such as TAVI, AAA, and LVAD implantation, Apica Cardiovascular's innovative approach minimizes blood loss and offers a less invasive alternative for patients. Having successfully demonstrated the concept in animal and cadaver models, the company is now progressing towards initial clinical trials.